Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or inactivating genes. Precisely fixing disease-causing mutations is far more ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Researchers developed a new gene-editing strategy that dramatically boosts the effectiveness of gene therapies in the liver, a breakthrough that could lead to new treatments for about 700 genetic ...

Liver hepatocyte organoids derived from normal (left) or mutant (right) mice showing accumulation of lipids (in green). Higher levels of lipids accumulate as big droplets inside each cell (nuclei ...

A more recent approach is transplantation of mature liver cells, known as hepatocytes. “The problem is obtaining sufficient quantities of fully functioning hepatocytes,” says Ochiya.

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

as cell membrane stabilisers and permeability regulators that prevent hepatotoxic agents from entering hepatocytes; (iii) as promoters of ribosomal RNAsynthesis, stimulating liver regeneration ...

A research team led by the Guangzhou Institutes of Biomedicine and Health of the Chinese Academy of Sciences, in ...